Mass. Lottery win: Gas station customer fills more than their gas tank
A trip to the gas station filled the pockets of the beneficiary of a trust based in Milton recently.
Trustee Matthew Marcus, representing the B&C Trust of Milton, claimed the second of three $10 million grand prizes in the Massachusetts State Lottery's '$10,000,000 Lucky Bucks' scratch ticket.
Marcus claimed the prize in the form of a one-time payment of $6,500,000 before taxes in lieu of a $500,000 annuity over 20 years.
Mobil, 145 Sharon St. in Stoughton, received a $50,000 bonus for selling the winning ticket.
More winning: Mass Lottery win: Man's grandson benefits from scratch ticket win
More winning: What a Gloucester man is going to do with Mass Lottery winning ticket bought in Hingham
This article originally appeared on The Patriot Ledger: Mass. Lottery: $10 million scratch ticket prize won in Stoughton
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Marcus & Millichap's IPA Capital Markets Division Arranges a $77.3 Million Non-Recourse Industrial Construction Loan in Savannah, Georgia
SAVANNAH, Ga., June 13, 2025--(BUSINESS WIRE)--IPA Capital Markets, a division of Marcus & Millichap (NYSE:MMI) specializing in capital markets services for major private and institutional clients, has arranged $77.3 million in financing for the construction of Central Port Logistics Tract 3, an industrial property located in Savannah, Georgia. The financing was secured by Dallas-based IPA Capital Markets' executive managing director Sunny Sajnani and associate director Travis Headapohl, on behalf of their client, Capital Development Partners (CDP) based in Savannah. Sajnani stated: "The level of lender interest for this project is a testament to Capital Development Partners and their ability to develop high quality logistics and distribution facilities in desired port markets. A national life company embraced the opportunity for this attractive financing and delivered competitive terms. This project provided a financing opportunity that offered scale, backed by the strength of the Port of Savannah." Central Port Logistics Tract 3 will consist of three speculative industrial buildings totaling 1,222,560 rentable square feet near the Port of Savannah. CDP anticipates the project will be fully leased and tenant-occupied by November 2026. These buildings are part of the larger Central Port Logistics Center, where CDP has delivered large-scale industrial projects, including a 982,800-square-foot building fully leased to Plastic Express, a 1,456,000-square-foot facility nearing stabilization, and two recently delivered 150,000-square-foot flex warehouses. "The non-recourse, life company construction loan will provide funds to complete the vertical construction as well as lease-up of the project," Sajnani said. About IPA Capital Markets IPA Capital Markets is a division of Marcus & Millichap (NYSE: MMI). IPA Capital Markets provides major private and institutional clients with commercial real estate capital markets financing solutions, including debt, mezzanine financing, preferred and joint venture equity, and sponsor equity. For more information, please visit About Marcus & Millichap, Inc. (NYSE: MMI) Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. Marcus & Millichap closed 7,836 transactions with a sales volume of approximately $49.6 billion in 2024. The company had 1,712 investment sales and financing professionals in more than 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate at year end. For additional information, please visit View source version on Contacts Gina Relva, VP of Public Relations Sign in to access your portfolio
Business Wire
3 hours ago
- Business Wire
Marcus & Millichap's IPA Capital Markets Division Arranges a $77.3 Million Non-Recourse Industrial Construction Loan in Savannah, Georgia
SAVANNAH, Ga.--(BUSINESS WIRE)-- IPA Capital Markets, a division of Marcus & Millichap (NYSE:MMI) specializing in capital markets services for major private and institutional clients, has arranged $77.3 million in financing for the construction of Central Port Logistics Tract 3, an industrial property located in Savannah, Georgia. The financing was secured by Dallas-based IPA Capital Markets' executive managing director Sunny Sajnani and associate director Travis Headapohl, on behalf of their client, Capital Development Partners (CDP) based in Savannah. Marcus & Millichap's IPA Capital Markets Division Arranges a $77.3 Million Non-Recourse Industrial Construction Loan in Savannah, Georgia Share Sajnani stated: 'The level of lender interest for this project is a testament to Capital Development Partners and their ability to develop high quality logistics and distribution facilities in desired port markets. A national life company embraced the opportunity for this attractive financing and delivered competitive terms. This project provided a financing opportunity that offered scale, backed by the strength of the Port of Savannah.' Central Port Logistics Tract 3 will consist of three speculative industrial buildings totaling 1,222,560 rentable square feet near the Port of Savannah. CDP anticipates the project will be fully leased and tenant-occupied by November 2026. These buildings are part of the larger Central Port Logistics Center, where CDP has delivered large-scale industrial projects, including a 982,800-square-foot building fully leased to Plastic Express, a 1,456,000-square-foot facility nearing stabilization, and two recently delivered 150,000-square-foot flex warehouses. 'The non-recourse, life company construction loan will provide funds to complete the vertical construction as well as lease-up of the project,' Sajnani said. About IPA Capital Markets IPA Capital Markets is a division of Marcus & Millichap (NYSE: MMI). IPA Capital Markets provides major private and institutional clients with commercial real estate capital markets financing solutions, including debt, mezzanine financing, preferred and joint venture equity, and sponsor equity. For more information, please visit About Marcus & Millichap, Inc. (NYSE: MMI) Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. Marcus & Millichap closed 7,836 transactions with a sales volume of approximately $49.6 billion in 2024. The company had 1,712 investment sales and financing professionals in more than 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate at year end. For additional information, please visit
Yahoo
18 hours ago
- Yahoo
The European Commission Approves Alnylam's AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). A researcher studying genetic medicines under a microscope in a biopharmaceutical laboratory. As a result, AMVUTTRA is the first and only RNAi treatment approved in the EU for transthyretin amyloidosis symptoms that show as cardiomyopathy and polyneuropathy. The HELIOS-B Phase 3 research, which revealed a 36% mortality reduction over 42 months and a 28% decrease in all-cause mortality and recurrent cardiovascular events, served as the basis for the approval. More than 6,000 patient-years of safety data support the quarterly administration of the medication. The drug is already authorized in Brazil and the United States. Up to 100,000 individuals in Europe have ATTR amyloidosis, mostly as cardiomyopathy. An RNAi treatment called vutrisiran provides continuous knockdown by stopping TTR production at its source with quarterly injections. Functional and quality-of-life gains were validated by the HELIOS-B trial, which involved patients on SGLT2 inhibitors and tafamidis. Elevations of liver enzymes and injection site responses are frequent adverse effects. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is an innovator in the investigation of RNA interference medicines. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
